Log in to search using one of your social media accounts:


Kadmon begins Phase IIa Portion of KD020 study

Kadmon has started the Phase IIa portion of a Phase Ib/IIa study of KD020 in autosomal dominant polycystic kidney disease (ADPKD), following unanimous recommendation of the study's data safety committee.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

More News: Pharmaceuticals | Polycystic Kidney Disease | Study | Urology & Nephrology